24-month differences in genitourinary and gastrointestinal change scores were noninferior for HYPORT versus COPORT

Small, but significant reduction seen in prostate cancer deaths, but no reduction seen in all-cause mortality

Large increases in prostate cancer expected due to changing age structure and improving life expectancy

Wearable, smartphone-controlled, rechargeable device effective for reducing voiding frequency; is safe in overactive bladder

Patient-tailored biopsy decisions still maintain high sensitivity

Additionally, proportion of patients who accessed their reports before the ordering provider increased

57.1 percent of physicians received payments; median payment was $48, but considerable variation seen in payments

Short- or longer-term relugolix achieves sustained castration in patients with localized and advanced prostate cancer

Video visits less likely among older patients and those without internet access

Greatest concerns are around physician well-being, health care spending, and equity